Stoke Therapeutics Inc
Research Stoke Therapeutics Inc (STOK) on Bullrun: market cap USD 2.09B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSTOK
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.09B
- Financial periodQ2 2026
- RevenueUSD 9.33M
- Net income-USD 61.62M
- Free cash flow-USD 58.56M
Valuation Snapshot
latest market cap is USD 2.09B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 184.42M | -USD 6.89M | USD 44.92M | n/a | -0.12 | USD 84.22M | USD 3.01M | USD 352.46M |
| FY2024 | USD 36.56M | -USD 88.98M | -USD 87.05M | n/a | -1.65 | USD 127.98M | USD 2.32M | USD 229.02M |
| FY2023 | USD 8.78M | -USD 104.70M | -USD 82.68M | n/a | -2.38 | USD 191.44M | USD 2.06M | USD 159.57M |
| FY2022 | USD 12.41M | -USD 101.07M | -USD 35.83M | n/a | -2.6 | USD 113.56M | USD 2.08M | USD 184.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.09B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.87B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 595.98M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 234.88M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 363.95M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 885.29M | n/a | n/a | n/a |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Stoke Therapeutics Inc's market cap?
Stoke Therapeutics Inc's market capitalization is USD 2.09B.
What does Stoke Therapeutics Inc do?
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials.